Hoofddorp, the Netherlands, 8 January 2020. IGEA Pharma N.V. (SIX: IGPH) today announced that the extraordinary general meeting followed all recommendations of the company. The minutes of the extraordinary general meeting is available at igeapharma.nl/category/information-for-shareholders
IGEA is a group focused on health-tech products and devices operating on the US market. IGEA commercialize Alz1, an at-home lab testing kit to measure non ceruloplasmin bound copper (generally defined as “free” copper) in the bloodstream and Alz1 Tab, a natural dietary supplement designed to reduce and control heavy metal contents in the bloodstream. “Free” copper is a risk factor associated with Alzheimer’s and diabetes type II. Monitoring and normalizing “free” copper can contribute to reduce the risk of Alzheimer’s and diabetes type II respectively.
IGEA is listed on the SIX Swiss Exchange under the ticker IGPH and is headquartered in Hoofddorp, the Netherlands.
Vincenzo Moccia, CEO
Tel +31 23 568 94 94/ +39 340 583 09 33
Patrick Pozzorini, CFO
Tel +31 23 568 94 94/ +41 79 314 41 43
IGEA Pharma N.V.
Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA.
The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments, except as may be required by law.
Documents for download: